Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Frequency-Dependent Effects of Percutaneous Femoral Nerve Stimulation on Quadriceps Strength (Motor_pPNS)

10 de novembro de 2026 atualizado por: Xavier Picañol Parraga, Hospital Clinic of Barcelona

Femoral Nerve Stimulation on Knee Extension Strength in Patellar Tendinopathy: A Randomized Crossover Trial

Peripheral nerve stimulation (PNS) is used to manage musculoskeletal pain and may also influence the neural mechanisms involved in voluntary muscle activation. However, whether different stimulation protocols produce distinct effects on muscle strength in individuals with persistent musculoskeletal pain remains unclear.

This randomized, blinded, crossover clinical trial investigates the acute effects of three femoral nerve stimulation protocols on quadriceps muscle function in individuals with persistent patellar tendinopathy. Each participant receives three interventions in a randomized sequence, separated by washout periods of at least 7 days: (1) high-frequency percutaneous peripheral nerve stimulation (HF-pPNS; 100 Hz), (2) low-frequency percutaneous peripheral nerve stimulation (LF-pPNS; 2 Hz), and (3) sensory-level transcutaneous electrical nerve stimulation (s-TENS; 100 Hz). Percutaneous interventions are administered under ultrasound guidance, whereas s-TENS is delivered using surface electrodes.

Quadriceps maximal voluntary contraction (MVC) and rate of force development (RFD) are assessed before stimulation and at 2, 10, 15, and 30 minutes after each intervention. Pain experienced during muscle strength testing, intervention tolerability, and adverse events are also evaluated.

The primary objective is to determine whether these stimulation protocols produce different acute changes in voluntary quadriceps force production. The study also examines interindividual variability in motor responses and explores their associations with pain during voluntary contraction and baseline clinical status.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

19

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Barcelona
      • Barcelona, Barcelona, Espanha, 08020
        • Blanquerna University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 40 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria

  • Adults aged 18-40 years.
  • Individuals with clinically diagnosed patellar tendinopathy lasting ≥3 months.
  • Ultrasound findings consistent with patellar tendinopathy, including tendon thickening, hypoechoic areas, or neovascularization.
  • Pain during tendon-loading activities (e.g., jumping, running, or squatting).
  • Ability to perform maximal voluntary isometric quadriceps contractions and comply with all experimental procedures and sessions.
  • Ability and willingness to provide written informed consent prior to participation.

Exclusion Criteria

  • Knee surgery or traumatic knee injury within the preceding 12 months.
  • Partial or complete patellar tendon rupture.
  • Neurological or neuromuscular disorders affecting lower-limb motor function, including radiculopathy or peripheral neuropathy.
  • Contraindications to electrical stimulation or percutaneous procedures, including implanted electrical devices, skin infections, or open wounds at the stimulation site.
  • Use of analgesics or anti-inflammatory medications, or receipt of corticosteroid injections, within the preceding 48 hours.
  • Participation in another interventional study within the preceding 30 days.
  • Pregnancy or suspected pregnancy.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: High-frequency percutaneous peripheral nerve stimulation (HF-pPNS)

Participants receive HF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

High-frequency percutaneous peripheral nerve stimulation (HF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered at 100 Hz in five 5-second trains separated by 55-second rest intervals. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.

Outros nomes:
  • HF-pPNS
Experimental: Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS)

Participants receive LF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered continuously at 2 Hz for 16 minutes. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.

Outros nomes:
  • LF-pPNS
Comparador Ativo: Sensory-level transcutaneous femoral nerve stimulation (s-TENS)

Participants receive s-TENS targeting the femoral nerve as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

Sensory-level transcutaneous electrical nerve stimulation (s-TENS) is administered targeting the femoral nerve at the inguinal level. The femoral nerve is identified under ultrasound guidance (SonoScape E1 Exp, SonoScape Medical Corp., China), and a self-adhesive surface electrode (5 × 5 cm) is positioned over the nerve. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Electrical stimulation is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Spain), generating symmetrical biphasic pulses continuously at 100 Hz for 16 minutes. Intensity is individually adjusted to elicit a clear paresthetic sensation without visible quadriceps contraction. Each participant receives one s-TENS session, with a minimum 7-day washout between crossover conditions.

Outros nomes:
  • s-TENS

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Quadriceps Maximal Isometric Voluntary Contraction
Prazo: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

Quadriceps maximal voluntary isometric contraction (MVC) is measured on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants are seated with the hip flexed at 90° and the knee positioned at 60°. Following a standardized warm-up and familiarization procedure, participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals. Real-time visual force feedback is provided, and participants are instructed to contract as fast and as hard as possible from a relaxed state. MVC is defined as the highest peak force recorded across the three trials, expressed in Newtons (N). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).

Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Quadriceps Rate of Force Development
Prazo: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

Quadriceps rate of force development (RFD) is assessed on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals, while instructed to contract as fast and as hard as possible. RFD is calculated from the force-time curve as the slope of force increase during the first 250 milliseconds following contraction onset, expressed in Newtons per second (N/s). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).

Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.
Incidence of Adverse Events Assessed Through Post-Intervention Questionnaires
Prazo: Immediately after each intervention session.

Adverse events potentially associated with peripheral nerve stimulation are assessed using a structured questionnaire completed at the end of each experimental session. Participants report the presence and intensity of sensory symptoms (pain, burning, itching), local skin reactions (erythema, swelling, bruising), and systemic symptoms (fatigue, headache, nausea). Additional unexpected symptoms can also be reported. Symptom intensity is assessed using a numerical rating scale (NRS; 0-10). Adverse events are recorded by type and severity, and their incidence is expressed as the number and percentage of participants reporting each event under each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS). Differences in adverse event frequency and intensity are evaluated across stimulation conditions.

Immediately after each intervention session.
Pain Intensity Evoked by Quadriceps Contraction
Prazo: Immediately after post-intervention quadriceps strength testing during each experimental session.

Pain intensity experienced during quadriceps maximal voluntary isometric contraction (MVC) is assessed using a 10-cm visual analog scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants report the intensity of pain experienced during the strength-testing procedure immediately after its completion. Pain scores are recorded for each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS) to characterize pain experienced during voluntary force production and explore its association with changes in quadriceps strength.

Immediately after post-intervention quadriceps strength testing during each experimental session.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de setembro de 2025

Conclusão Primária (Real)

14 de janeiro de 2026

Conclusão do estudo (Real)

4 de novembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

15 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de novembro de 2025

Primeira postagem (Real)

20 de novembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified individual participant data underlying the results reported in the published article will be available from the corresponding author upon reasonable request. These data may include maximal voluntary contraction (MVC), rate of force development (RFD), pain ratings, baseline clinical characteristics, stimulation conditions, and adverse events. Data sharing will be subject to applicable ethical approvals, institutional policies, and data protection requirements. Requests will be evaluated based on their scientific rationale and methodological soundness.

Prazo de Compartilhamento de IPD

De-identified individual participant data will be available upon reasonable request beginning at the time of publication of the study results and for a period of five years thereafter.

Critérios de acesso de compartilhamento IPD

De-identified individual participant data underlying the published results will be available to qualified researchers upon reasonable request to the corresponding author. Requests must include a scientifically sound research proposal describing the intended use of the data. Access will be subject to approval by the research team and compliance with applicable ethical, institutional, and data protection requirements. A data-sharing agreement may be required before data transfer.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever